Valiant Organics Ltd

Valiant Organics Ltd has announced its 21st Annual General Meeting (AGM) will be held on Tuesday, September 29, 2026, at 11:30 A.M. IST. The meeting will be conducted virtually via Video Conferencing (VC) / Other Audio-Visual Means (OAVM), without physical attendance. The notice of the AGM, along with the Annual Report for the Financial Year 2025-26, is being sent via email to members with registered email addresses. Shareholders without registered emails will receive letters with a web-link to the Annual Report. The Annual Report, available on the company's website (www.valiantorganics.com), covers financial statements, management discussion, and corporate governance details.

Valiant Organics Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26. This report, filed in accordance with Listing Regulations, details the company's performance across various ESG parameters. The BRSR is available on the company's website and covers standalone disclosures. The company's primary business activity is the manufacturing and marketing of chlorophenols, benzene-based specialty chemicals, and other chemical intermediates, contributing 100% of its turnover. Key product segments include Agro-chemicals (24%), Dyes & Pigments (45%), Pharmaceutical (21%), and Cosmetics & Specialty Chemicals (10%). The company operates across 29 states in India and serves 4 international markets, with exports accounting for approximately 5% of its total turnover. The report focuses on B2B customers in the pharmaceutical, agrochemical, dyes and pigments, and industrial chemical sectors.

Valiant Organics Ltd has announced its 21st Annual General Meeting (AGM) scheduled for September 29, 2026, at 11:30 AM IST, to be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The company has also released its Annual Report for the Financial Year 2025-26. The report, along with the AGM notice, will be sent via email to members with registered email addresses and a web-link will be sent to others. The Annual Report details the company's performance highlights, strategies, financial statements, and corporate governance. The company emphasizes a year of 'recalibration' in FY 2025-26, focusing on cost optimization, capacity utilization, and process efficiency, leading to improved margins and profitability.

Valiant Organics Ltd announced a change in its registered office address, subject to shareholder approval at the upcoming AGM. The company's Board of Directors, meeting on August 12, 2026, also approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. Additionally, the re-appointment of Shri Sathiababu K. Kallada as Managing Director for a three-year term was approved, pending shareholder consent. The corporate office has also been relocated to Vikhroli (West), Mumbai.

Valiant Organics Ltd announced the relocation of its corporate office to 701-A, Tower-B, Embassy 247 Park, Vikhroli (West), Mumbai. The Board of Directors also approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the limited review report. Additionally, Shri Sathiababu K. Kallada was re-appointed as Managing Director for three years from May 24, 2027. The company also plans to shift its registered office, subject to shareholder approval.

Valiant Organics Ltd announced that its Board of Directors, at a meeting held on August 12, 2026, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board also approved the re-appointment of Shri Sathiababu K. Kallada as Managing Director for a three-year term commencing May 24, 2027, subject to shareholder approval. Additionally, the company plans to shift its registered office, subject to shareholder consent. The meeting also covered the limited review report of the statutory auditors.

Valiant Organics Ltd announced that its Board of Directors, at a meeting held on August 12, 2026, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company also approved the re-appointment of Shri Sathiababu K. Kallada as Managing Director for three years from May 24, 2027, subject to shareholder approval. Additionally, the Board approved the shifting of the company's registered office from Mulund, Mumbai, to Tarapur, Palghar, Maharashtra, also subject to shareholder approval. The corporate office has been relocated to Vikhroli, Mumbai.

Valiant Organics's consolidated PAT for Q1 FY27 (quarter ended 30 June 2026) came in at ₹29.26 Cr, up 256.8% YoY from ₹8.20 Cr and up 86.2% QoQ from ₹15.72 Cr, on revenue of ₹231.54 Cr (+13.3% YoY, +6.3% QoQ). Standalone tells a similar but less dramatic story: PAT of ₹21.82 Cr, up 187.9% YoY and 44.3% QoQ on identical revenue of ₹231.54 Cr — both bases point to a genuine operating improvement, not just a consolidation artifact, though the gap between the two (257% vs 188% YoY PAT growth) is real and traces to one large item flagged below. Basic EPS was ₹10.44 (consolidated) versus ₹2.93 a year ago and ₹5.61 last quarter. The primary driver is the Pharma segment, newly split out as a separate reportable segment this quarter (Ind AS 108, per the company's own note): standalone Pharma segment result swung from a ₹0.83 Cr loss in Q1 FY26 to a ₹8.99 Cr profit this quarter, while the base Speciality Chemicals segment grew profit 44.3% YoY to ₹25.06 Cr on 16.6% higher segment revenue. On top of this standalone-level improvement, the consolidated statement carries a ₹7.23 Cr share of profit from an indirect associate (Valiant Laboratories Limited, held via Dhanvallabh Ventures LLP) — up from just ₹0.62 Cr a year ago and ₹0.61 Cr last quarter, a roughly 12x jump that alone adds about ₹6.6 Cr to consolidated PAT beyond what standalone growth would imply; stripping that swing out, adjusted consolidated PAT growth is closer to +176% YoY, still strong but not the full +257% headline. Finance costs eased to ₹5.13 Cr from ₹6.05 Cr YoY, aiding the bridge, while employee costs rose 10.6% YoY. Net margin (PAT/total income) expanded to 12.46% from 3.99% YoY and 7.09% last quarter, consistent with the segment-level profitability shift rather than a one-line accounting item. There is no consensus estimate on record for this stock and a web search turned up no Q1 FY27 brokerage previews, so vs-street cannot be assessed; the company also carries no formal prior guidance in our records or found via search, so beat/miss/met cannot be judged either — this print stands on its own numbers. No management press release accompanied the filing (only the board-outcome letter), so there is no company framing to reconcile against the figures. Alongside the results, the board approved the re-appointment of Managing Director Sathiababu K. Kallada for a fresh three-year term (May 2027-May 2030) and a shift of the registered office to Tarapur, Boisar (Palghar), with the corporate office already relocated to Vikhroli, Mumbai — both governance/administrative items unrelated to the quarter's numbers. Separately, a proposed restructuring under which Valiant Organics would have exited Dhanvallabh Ventures LLP in exchange for a direct stake in Valiant Laboratories was called off via a cancelled postal ballot on 18 June 2026, so the associate structure behind this quarter's ₹7.23 Cr profit-share line remains unchanged going into Q2.

Valiant Organics Ltd has announced that its Board of Directors will convene on August 12, 2026. The primary agenda item is to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The trading window for company securities will remain closed until August 14, 2026, following this announcement.

Valiant Organics Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from Wednesday, July 01, 2026, and will remain in effect until 48 hours after the declaration of financial results for the quarter ended June 30, 2026. The measure aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct, restricting access for directors, promoters, designated persons, and their immediate relatives to prevent potential insider trading.